Zacks: Brokerages Anticipate Arrowhead Pharmaceuticals, Inc. (ARWR) to Announce -$0.13 Earnings Per Share
Brokerages forecast that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) will report ($0.13) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Arrowhead Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.10). Arrowhead Pharmaceuticals reported earnings of ($0.31) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 58.1%. The business is expected to issue its next earnings report on Wednesday, December 13th.
On average, analysts expect that Arrowhead Pharmaceuticals will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.50) to ($0.41). For the next year, analysts expect that the company will post earnings of ($0.71) per share, with EPS estimates ranging from ($0.88) to ($0.43). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.06. The business had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%.
A number of analysts have recently issued reports on the stock. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Piper Jaffray Companies reaffirmed a “hold” rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $1.80.
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) traded up 0.29% during mid-day trading on Tuesday, reaching $3.44. 2,677,248 shares of the company’s stock traded hands. Arrowhead Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $8.09. The stock’s market cap is $257.22 million. The firm’s 50 day moving average price is $2.23 and its 200-day moving average price is $1.85.
Hedge funds and other institutional investors have recently made changes to their positions in the company. LMR Partners LLP bought a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $467,000. Wells Fargo & Company MN lifted its stake in shares of Arrowhead Pharmaceuticals by 144.8% in the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock worth $278,000 after purchasing an additional 88,933 shares during the period. SG Americas Securities LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 287.9% in the 1st quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 74,776 shares during the period. UBS Asset Management Americas Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 414.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 53,500 shares during the period. Finally, Virtu KCG Holdings LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 53,215 shares during the period. 20.63% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Arrowhead Pharmaceuticals, Inc. (ARWR) to Announce -$0.13 Earnings Per Share” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/13/zacks-brokerages-anticipate-arrowhead-pharmaceuticals-inc-arwr-to-announce-0-13-earnings-per-share.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.